Proffitt & Goodson’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $996K | Sell |
35,469
-110
| -0.3% | -$2.93K | 0.15% | 60 |
|
|
2025
Q4 | $886K | Buy |
35,579
+31,754
| +830% | +$801K | 0.12% | 71 |
|
|
2025
Q3 | $97.5K | Sell |
3,825
-432
| -10% | -$10.7K | 0.01% | 144 |
|
|
2025
Q2 | $103K | Buy |
4,257
+795
| +23% | +$18.5K | 0.02% | 131 |
|
|
2025
Q1 | $87.7K | Buy |
3,462
+6
| +0.2% | +$157 | 0.01% | 143 |
|
|
2024
Q4 | $91.7K | Buy |
3,456
+7
| +0.2% | +$190 | 0.02% | 138 |
|
|
2024
Q3 | $99.8K | Buy |
3,449
+6
| +0.2% | +$175 | 0.02% | 141 |
|
|
2024
Q2 | $96.3K | Sell |
3,443
-120
| -3% | -$3.3K | 0.02% | 135 |
|
|
2024
Q1 | $98.9K | Buy |
3,563
+1,068
| +43% | +$29.6K | 0.02% | 131 |
|
|
2023
Q4 | $71.8K | Buy |
2,495
+400
| +19% | +$12.1K | 0.01% | 143 |
|
|
2023
Q3 | $69.5K | Sell |
2,095
-20,991
| -91% | -$742K | 0.01% | 147 |
|
|
2023
Q2 | $847K | Buy |
23,086
+411
| +2% | +$16K | 0.17% | 65 |
|
|
2023
Q1 | $925K | Hold |
22,675
| – | – | 0.19% | 60 |
|
|
2022
Q4 | $1.16M | Buy |
22,675
+138
| +0.6% | +$6.62K | 0.25% | 44 |
|
|
2022
Q3 | $986K | Buy |
22,537
+316
| +1% | +$15.4K | 0.21% | 49 |
|
|
2022
Q2 | $1.17M | Sell |
22,221
-83
| -0.4% | -$4.23K | 0.24% | 47 |
|
|
2022
Q1 | $1.16M | Sell |
22,304
-1,364
| -6% | -$70.8K | 0.21% | 52 |
|
|
2021
Q4 | $1.4M | Buy |
23,668
+3,817
| +19% | +$189K | 0.25% | 50 |
|
|
2021
Q3 | $854K | Sell |
19,851
-131
| -0.7% | -$5.8K | 0.16% | 62 |
|
|
2021
Q2 | $782K | Buy |
19,982
+1,590
| +9% | +$61.8K | 0.14% | 66 |
|
|
2021
Q1 | $666K | Buy |
18,392
+39
| +0.2% | +$1.39K | 0.13% | 68 |
|
|
2020
Q4 | $676K | Buy |
18,353
+831
| +5% | +$30.5K | 0.14% | 65 |
|
|
2020
Q3 | $610K | Buy |
17,522
+2,450
| +16% | +$85.9K | 0.13% | 69 |
|
|
2020
Q2 | $468K | Buy |
15,072
+85
| +0.6% | +$2.89K | 0.1% | 68 |
|
|
2020
Q1 | $464K | Sell |
14,987
-5,607
| -27% | -$191K | 0.12% | 64 |
|
|
2019
Q4 | $766K | Sell |
20,594
-5,711
| -22% | -$203K | 0.17% | 63 |
|
|
2019
Q3 | $897K | Buy |
26,305
+3,656
| +16% | +$133K | 0.22% | 53 |
|
|
2019
Q2 | $931K | Sell |
22,649
-46
| -0.2% | -$1.83K | 0.23% | 49 |
|
|
2019
Q1 | $914K | Buy |
22,695
+22,623
| +31,421% | +$906K | 0.23% | 50 |
|
|
2018
Q4 | $3K | Hold |
72
| – | – | ﹤0.01% | 147 |
|
|
2018
Q3 | $3K | Buy |
+72
| New | +$2.77K | ﹤0.01% | 136 |
|
Other funds holding PFE
VCM
VPM
Proffitt & Goodson's PFE Position: Q1 2026 in Review
Proffitt & Goodson reduced its Pfizer (PFE) stake by 0.31% in Q1 2026, selling an estimated $2.93K and leaving 35,469 shares worth $996K. The position accounts for 0.15% of the portfolio, ranked #60.
Proffitt & Goodson first reported a position in PFE in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.4M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Proffitt & Goodson held 35,469 shares of Pfizer worth $996K as of Q1 2026.
- Proffitt & Goodson sold 110 Pfizer shares in Q1 2026, an estimated $2.93K.
- Pfizer made up 0.15% of Proffitt & Goodson's portfolio in Q1 2026, its #60 holding.
- Proffitt & Goodson first reported a position in Pfizer in Q3 2018 and has held it in 31 quarters since.
- Proffitt & Goodson's Pfizer position peaked at $1.4M in Q4 2021.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Proffitt & Goodson's 13F filing for Q1 2026, filed 6 May 2026.